In-Silico Antibody Development with AlphaBind Using NVIDIA BioNeMo and AWS HealthOmics

Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range…

Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range of diseases, from cancer to autoimmune disorders. Their specificity reduces the likelihood of off-target effects, making them safer and often more effective than small-molecule drugs for complex conditions. As a result…

Source

Leave a Reply

Your email address will not be published.

Previous post New NVIDIA Certifications Expand Professionals’ Credentials in AI Infrastructure and Operations
Next post Introducing NVIDIA cuPQC for GPU-Accelerated Post-Quantum Cryptography